



The Indonesian Journal of General Medicine

A Comprehensive Literature Review of Diagnosis and Management of Multi Drug Resistant Tuberculosis

¹ Erick Persson Jeffry, ¹ Charles Sanjaya Seikka

¹ Faculty of Medicine, Veterans National Development University, Special
Region of Jakarta, Indonesia

² Internal Medicine Consultant, Kebonjati General Hospital, Bandung City,
Indonesia

Correspondence : erick.persson86@gmail.com

Article History :

Received date : 2024/10/26
Revised date : 2024/11/13
Accepted date : 2024/12/16
Published date : 2025/01/08



Copyright: © 2024 by the
authors. Submitted for possible
open access publication under
the terms and conditions of the
Creative Commons Attribution
(BY NC) license
(<https://creativecommons.org/licenses/by-nc/4.0/>).

ISSN 3048-104X



ABSTRACT

Background: The review of the literature on the diagnosis and management of multidrug-resistant tuberculosis (MDR-TB) reveals a pressing global health challenge characterized by complex factors influencing its prevalence and treatment. (Chhabra et al., 2012) lay the groundwork by identifying systemic issues such as inadequate healthcare resources and poor case detection as significant contributors to the MDR-TB epidemic. **Literature Review:** (J. Sloan & M. Lewis, 2016) further contribute to the discourse by exploring novel treatments and their applicability in low-resource environments. They emphasize the importance of improved diagnostics and the integration of new therapeutic strategies, while also addressing the financial barriers associated with MDR-TB treatment. (Kolloli & Subbian, 2017) shift the focus to host-directed therapies, arguing for innovative management strategies to address the complexities introduced by co-infections and chronic illnesses. They call for a reevaluation of traditional treatment regimens, particularly for patients with MDR- and extensively drug-resistant tuberculosis (XDR-TB), highlighting the need for approaches that enhance effectiveness. (Yadav, 2023) reviews recent advancements in MDR-TB research, particularly in diagnostic technologies and treatment methodologies. The article reinforces the urgency of addressing the global challenge posed by MDR-TB through innovative strategies that facilitate faster and more accurate diagnosis, ultimately aiming for improved patient outcomes. **Conclusion:** In conclusion, the literature collectively illustrates the dynamic and intricate landscape of MDR-TB management. The articles underscore the critical need for continued research, enhanced diagnostics, and innovative treatment strategies to effectively combat this growing public health crisis. A multifaceted approach that includes international collaboration, financial investment, and the integration of new technologies is essential for addressing the challenges posed by MDR-TB and improving patient outcomes.

Keyword: Diagnosis, Management, Multi Drug Resistant Tuberculosis

INTRODUCTION

The literature surrounding the diagnosis and management of multidrug-resistant tuberculosis (MDR-TB) reveals a complex interplay of challenges, advancements, and strategies aimed at combating this significant public health threat. The foundational work by Chhabra et al. (Chhabra et al., 2012) highlights the critical issues contributing to the MDR-TB epidemic, including inadequate healthcare resources, poor case detection, and inappropriate treatment regimens. They emphasize the importance of optimizing treatment protocols and implementing rapid diagnostic tools, which have shown promise in improving patient outcomes and prognosis. This article sets the stage for understanding the multifaceted nature of MDR-TB management.

In the subsequent year, Giyose (Giyose, 2013) further elaborates on the global burden of MDR-TB, particularly in high-prevalence countries like India and China. The study underscores the limitations faced in resource-limited settings,

where advanced laboratory diagnostics are often unavailable. Giyose outlines a structured management approach that includes drug susceptibility testing and monitoring compliance, emphasizing the need for comprehensive strategies to address the rising prevalence of drug-resistant strains.

Sloan and Lewis (J. Sloan & M. Lewis, 2016) contribute to this discourse by exploring novel treatments and their applicability in low-resource environments. They advocate for improved diagnostics and the integration of new therapeutic strategies, while also addressing the financial barriers associated with MDR-TB treatment. Their insights into the importance of adaptive trial designs and international collaboration are crucial for advancing treatment protocols and ensuring that new drugs are accessible without compromising safety.

Kolloli and Subbian (Kolloli & Subbian, 2017) shift the focus to host-directed therapies, highlighting the pressing need for innovative management strategies in light of the complexities introduced by co-

infections and chronic illnesses. They stress that traditional treatment regimens may fall short, particularly in cases of MDR- and extensively drug-resistant tuberculosis (XDR-TB), thus calling for a reevaluation of current therapeutic approaches to enhance effectiveness.

Yadav (Yadav, 2023) reviews recent advancements in MDR-TB research, particularly in diagnostic technologies and treatment methodologies. This article reinforces the urgency of addressing the global challenge posed by MDR-TB through innovative strategies that facilitate faster and more accurate diagnosis, ultimately aiming for improved patient outcomes.

Vishwakarma et al. (Vishwakarma et al., 2023) delve into the diagnostic landscape of MDR-TB, contrasting traditional phenotyping methods with molecular detection techniques. They highlight the advantages and limitations of rapid diagnostic tests, such as the GeneXpert and TrueNat, while emphasizing the need for cost-effective and efficient management

strategies to curb the spread of MDR-TB.

Finally, Karnan et al. (Karnan et al., 2024) provide a comprehensive analysis of treatment regimens within the framework of programmatic management of drug-resistant tuberculosis (PMDT). Their examination of long versus short treatment regimens underscores the necessity of tailoring approaches to individual patient needs and the importance of ongoing monitoring and healthcare professional training. This review encapsulates the evolving nature of MDR-TB management, advocating for a collaborative and nuanced approach to effectively address this persistent global health challenge.

Together, these articles illustrate the dynamic and intricate landscape of MDR-TB management, highlighting the need for continued research, improved diagnostics, and innovative treatment strategies to effectively combat this growing public health crisis.

LITERATURE REVIEW

The article "Pharmacotherapy for multidrug resistant tuberculosis"

by (Chhabra et al., 2012) provides a comprehensive overview of the multifaceted challenges posed by multidrug-resistant tuberculosis (MDR-TB) and emphasizes the critical need for effective management strategies. The authors argue that the current epidemic of MDR-TB is primarily attributable to systemic issues, including inadequate resources for tuberculosis control programs, poor case detection, and suboptimal treatment regimens. This perspective highlights the urgency of addressing these foundational problems to improve outcomes for affected patients.

A significant contribution of the article is its discussion on optimizing treatment regimens. The authors assert that the implementation of rapid diagnostic techniques and drug susceptibility testing (DST) for both first- and second-line drugs has markedly enhanced clinical outcomes for patients with MDR-TB. This assertion underscores the importance of timely and accurate diagnosis in the management of MDR-TB, which is crucial for tailoring effective treatment plans.

Furthermore, the article delves into the pharmacotherapy options available for MDR-TB, detailing the various drugs utilized in treatment protocols. The authors provide a thorough examination of common adverse drug reactions associated with these medications, which is essential for clinicians to anticipate and manage potential complications during treatment. By highlighting the adverse effects and their management, the review equips healthcare providers with practical knowledge to mitigate risks associated with MDR-TB pharmacotherapy.

The authors also stress the importance of preventing the development and spread of MDR-TB, framing it as a "man-made disease." This perspective not only calls attention to the role of public health initiatives in controlling the spread of MDR-TB but also emphasizes the ethical responsibility of healthcare systems to ensure appropriate treatment and prevention strategies are in place.

The article titled "Strategies used to implement the national

guidelines on preventing and early management of multi-drug resistant tuberculosis (MDR-TB) at the buffalo city municipality clinics in East London Eastern Cape province" by (Giyose, 2013) provides a critical examination of the growing public health crisis posed by multi-drug resistant tuberculosis (MDR-TB). The author highlights the alarming global statistics, indicating that in 2008, an estimated 440,000 cases of MDR-TB emerged worldwide, with India and China accounting for nearly half of these cases. This data underscores the urgent need for effective diagnosis and management strategies, particularly in resource-limited settings.

Giyose notes that the prevalence of drug-resistant tuberculosis has reached unprecedented levels, with over three-quarters of estimated cases occurring in previously untreated patients. This observation raises significant concerns regarding the effectiveness of current TB control measures and the inherent challenges in diagnosing MDR-TB. The article emphasizes that laboratory methods required for accurate diagnosis are often lacking in

many regions, hindering timely and appropriate treatment. This gap in diagnostic capacity is particularly critical as the treatment of MDR-TB is not only longer and more complicated than that of drug-susceptible TB but also significantly more expensive and less successful.

The management strategies discussed in the article involve a comprehensive approach, which includes drug susceptibility testing, rapid tracing and evaluation of contacts, and stringent monitoring of treatment compliance. Giyose effectively argues that the responsibility for managing MDR-TB lies with the TB program at all levels, highlighting the need for coordinated efforts among healthcare providers to identify and treat patients promptly. The article also touches on the importance of understanding the factors that contribute to the development of drug-resistant TB. Identifying these factors in individual patients is crucial for health care providers to act swiftly in diagnosing potential cases of drug-resistant TB.

Moreover, the negative repercussions of MDR-TB for

individuals, TB control programs, and communities are starkly outlined. The difficulty in treating MDR-TB not only complicates individual patient outcomes but also poses a significant challenge to public health efforts aimed at controlling tuberculosis. Giyose's analysis underscores the critical need for enhanced strategies to improve diagnosis and management of MDR-TB, particularly in areas with limited resources.

The article titled "Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings" by (J. Sloan & M. Lewis, 2016) provides a comprehensive overview of the challenges and advancements in the diagnosis and management of multidrug-resistant tuberculosis (MDR-TB). The authors emphasize the critical need for improved diagnostics that can facilitate rapid and reliable identification of MDR-TB, which is a prerequisite for effective treatment. They argue that advancements in molecular testing and refinements in line probe assays are essential for detecting resistance to second-line drugs (SLDs), which

will ultimately enhance the management of MDR-TB.

One of the key insights from the article is the uncertainty surrounding the use of short multi-drug combinations for treating MDR-TB. The authors highlight that definitive data from ongoing clinical trials are necessary to establish the safety and efficacy of these combinations. This uncertainty is compounded by the evolving nature of treatment guidelines, which necessitates that healthcare providers remain adaptable and informed about the latest research findings. The authors propose that peer-to-peer consultation could be instrumental in standardizing treatment protocols and ensuring quality assurance in the application of new therapies.

Moreover, the article addresses the significant financial burden associated with MDR-TB treatment, which encompasses not only the costs of new drugs but also diagnostic tests, hospitalization, and follow-up care. The authors argue that any deficiencies in the comprehensive care package can lead to treatment failures, thus hindering efforts to

eliminate tuberculosis. This assertion underscores the importance of an integrated approach to managing MDR-TB, which includes both effective diagnostics and therapeutic strategies.

The discussion of new therapeutic strategies is particularly noteworthy, as the authors mention the potential to reduce reliance on injectable agents and shorten treatment durations. This is a crucial development, given the adverse effects and logistical challenges associated with longer treatment regimens. The authors call for international cooperation and sustained investment to optimize treatment regimens and expand access to innovative drugs, which is essential for combating the growing threat of MDR-TB.

The article "Host-Directed Therapeutic Strategies for Tuberculosis" by (Kolloli & Subbian, 2017) provides a comprehensive overview of the challenges posed by multi-drug resistant tuberculosis (MDR-TB) and highlights the pressing need for innovative therapeutic approaches. The authors

effectively contextualize the global burden of tuberculosis, particularly in developing countries, where the disease remains a significant health threat exacerbated by factors such as HIV co-infection and the presence of chronic conditions like diabetes.

One of the critical insights from the article is the acknowledgment of the limitations inherent in the current World Health Organization (WHO) recommended treatment regimen, which typically includes a combination of four first-line antibiotics: isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol. The authors emphasize that the rapid development of resistance to these drugs, particularly INH and RIF, can be attributed to both incorrect drug prescriptions and patient non-compliance. This situation has culminated in a significant rise in cases of MDR- and extensively drug-resistant tuberculosis (XDR-TB), with nearly half a million new MDR cases reported globally, alongside an alarming number of RIF-mono-resistant cases.

Kolloli and Subbian also delve into the implications of prolonged and complex anti-TB chemotherapy required for managing MDR- and XDR-TB. They note that the treatment not only incurs substantial financial costs but also poses a risk of severe adverse effects, which can further compromise patient adherence to treatment regimens. This critical evaluation of current treatment paradigms underscores the necessity for alternative management strategies that can effectively address the dual challenges of drug sensitivity and resistance.

Furthermore, the article calls for the exploration of host-directed therapies as a potential avenue for improving TB management. Such strategies may enhance the host's immune response to *Mycobacterium tuberculosis* (Mtb) and mitigate the adverse effects of conventional treatments. This perspective is particularly relevant given the increasing incidence of drug-resistant strains and the urgent need for novel therapeutic options.

In "Challenges & Solutions for Recent Advancements in Multi-

Drugs Resistance Tuberculosis: A Review," (Yadav, 2023) provides a comprehensive analysis of the contemporary challenges posed by multi-drug resistant tuberculosis (MDR-TB) and highlights recent advancements in diagnostic and treatment strategies. The article emphasizes that MDR-TB remains a significant global health threat, necessitating urgent attention and innovative solutions.

Yadav systematically discusses the complexities surrounding the diagnosis of MDR-TB, noting that traditional methods often fall short in terms of speed and accuracy. The author points out the limitations of conventional culture-based techniques, which can take weeks to yield results, thereby delaying appropriate treatment. In response to these challenges, the article reviews emerging technologies such as molecular diagnostics, which have demonstrated the potential to significantly reduce the time required for diagnosis. Techniques such as GeneXpert and next-generation sequencing are highlighted as pivotal in providing rapid and reliable identification of resistant strains.

Moreover, the review delves into treatment strategies for MDR-TB, noting that the management of this condition is complicated by the limited availability of effective drugs and the need for prolonged treatment regimens. Yadav discusses novel therapeutic approaches, including the use of bedaquiline and delamanid, which have shown promise in clinical settings. The author emphasizes the importance of individualized treatment plans that consider the patient's specific drug resistance patterns, thereby optimizing outcomes.

Yadav also addresses the role of public health initiatives in combating MDR-TB, advocating for enhanced surveillance systems and the integration of new diagnostic tools into existing healthcare frameworks. The article underscores the necessity of interdisciplinary collaboration among healthcare providers, researchers, and policymakers to develop comprehensive strategies that not only focus on treatment but also on prevention and control measures.

The article titled "Multi-Drug Resistance Tuberculosis (MDR-TB)

Challenges in India: A Review" by (Vishwakarma et al., 2023) provides a comprehensive overview of the diagnostic and management challenges associated with multi-drug resistant tuberculosis (MDR-TB) in India. The authors emphasize the importance of accurate and timely diagnosis as a crucial step in managing MDR-TB, detailing two primary methods for diagnosis: phenotyping drug susceptibility testing (DST) and molecular detection of drug-resistance gene mutations.

The review highlights the GeneXpert test as a pivotal tool in the diagnostic landscape for TB, particularly in endemic regions. This molecular diagnostic method is noted for its rapid turnaround time, allowing for TB diagnosis in under one hour and simultaneously testing for rifampicin resistance. However, the authors also point out significant limitations, such as the test's restricted sensitivity and the associated costs, which may hinder its widespread implementation. This critical evaluation of the GeneXpert underscores the need for a balanced understanding of its benefits and

drawbacks in the context of resource-limited settings.

Furthermore, the article discusses the broader implications of MDR-TB control, emphasizing the necessity of preventing the emergence of drug-resistant strains. The authors advocate for the Directly Observed Treatment, Short-course (DOTS) strategy as a fundamental approach to achieving this goal. They articulate that effective treatment not only aims to cure the patient but also plays a vital role in curbing the transmission of MDR-TB within communities.

The review also references the World Health Organization's (WHO) recommendations for the systematic management of drug-resistant tuberculosis, which provide a framework for health authorities and practitioners in addressing MDR-TB. By incorporating these guidelines, the authors suggest that healthcare systems can enhance their response to MDR-TB challenges, ultimately improving patient outcomes and reducing public health risks.

The article titled "A Comprehensive Review on Long vs.

Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT)" by (Karnan et al., 2024) provides an in-depth examination of the treatment landscape for MDR-TB, highlighting the critical nature of this public health issue and the complexities involved in its management. The authors effectively contextualize MDR-TB within the framework of PMDT, illustrating the necessity for targeted treatment strategies that address the unique challenges posed by drug-resistant strains of *Mycobacterium tuberculosis*.

One of the key insights from the review is the historical evolution of treatment regimens for MDR-TB, which has transitioned from longer, more arduous protocols to potentially shorter, more efficient ones. The discussion on the efficacy and safety profiles of these regimens is particularly relevant, as it underscores the importance of balancing treatment duration with patient adherence and overall health outcomes. The authors emphasize that while shorter regimens may improve patient

compliance, the selection of an appropriate regimen must be individualized based on specific patient factors, such as the extent of drug resistance, comorbid conditions, and previous treatment history.

The review also addresses the implementation challenges faced by PMDT programs, which include issues related to resource allocation, healthcare provider training, and the integration of advanced diagnostic tools. The authors advocate for continuous surveillance and monitoring to ensure that treatment protocols remain effective and adaptable to emerging resistance patterns. This proactive approach is critical in a landscape where the dynamics of drug resistance are constantly evolving.

Furthermore, the article highlights the necessity for collaborative efforts among healthcare professionals, policymakers, and researchers to enhance the management of MDR-TB. The authors call for a multifaceted strategy that includes ongoing education and training for healthcare providers, which is

essential for the effective implementation of PMDT guidelines and the overall improvement of patient outcomes.

CONCLUSION

The review of the literature on the diagnosis and management of multidrug-resistant tuberculosis (MDR-TB) reveals a pressing global health challenge characterized by complex factors influencing its prevalence and treatment. (Chhabra et al., 2012) lay the groundwork by identifying systemic issues such as inadequate healthcare resources and poor case detection as significant contributors to the MDR-TB epidemic. They argue for the optimization of treatment protocols and the implementation of rapid diagnostic tools to improve patient outcomes. This foundational perspective is critical as it highlights the need for effective management strategies in the face of rising drug resistance.

Building on this, (Giyose, 2013) provides a detailed examination of the global burden of MDR-TB, particularly in high-prevalence countries. The article

emphasizes the challenges faced in resource-limited settings, where advanced diagnostic capabilities are often lacking. (Giyose, 2013) advocates for a structured management approach that includes drug susceptibility testing and compliance monitoring, underscoring the necessity of comprehensive strategies to tackle the increasing prevalence of drug-resistant strains.

(J. Sloan & M. Lewis, 2016) further contribute to the discourse by exploring novel treatments and their applicability in low-resource environments. They emphasize the importance of improved diagnostics and the integration of new therapeutic strategies, while also addressing the financial barriers associated with MDR-TB treatment. Their insights into adaptive trial designs and international collaboration are essential for advancing treatment protocols and ensuring accessibility to new drugs.

(Kolloli & Subbian, 2017) shift the focus to host-directed therapies, arguing for innovative management strategies to address the complexities introduced by co-

infections and chronic illnesses. They call for a reevaluation of traditional treatment regimens, particularly for patients with MDR- and extensively drug-resistant tuberculosis (XDR-TB), highlighting the need for approaches that enhance effectiveness.

(Yadav, 2023) reviews recent advancements in MDR-TB research, particularly in diagnostic technologies and treatment methodologies. The article reinforces the urgency of addressing the global challenge posed by MDR-TB through innovative strategies that facilitate faster and more accurate diagnosis, ultimately aiming for improved patient outcomes.

(Vishwakarma et al., 2023) delve into the diagnostic landscape of MDR-TB, contrasting traditional phenotyping methods with molecular detection techniques. They highlight the advantages and limitations of rapid diagnostic tests, such as GeneXpert and TrueNat, emphasizing the need for cost-effective management strategies to curb the spread of MDR-TB.

Finally, (Karnan et al., 2024) provide a comprehensive analysis of treatment regimens within the framework of programmatic management of drug-resistant tuberculosis (PMDT). Their examination of long versus short treatment regimens underscores the necessity of tailoring approaches to individual patient needs and emphasizes the importance of ongoing monitoring and healthcare professional training.

In conclusion, the literature collectively illustrates the dynamic and intricate landscape of MDR-TB management. The articles underscore the critical need for continued research, enhanced diagnostics, and innovative treatment strategies to effectively combat this growing public health crisis. A multifaceted approach that includes international collaboration, financial investment, and the integration of new technologies is essential for addressing the challenges posed by MDR-TB and improving patient outcomes.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Chhabra, N., L. Aseri, M., Dixit, R., & Gaur, S., 2012. Pharmacotherapy for multidrug resistant tuberculosis. ncbi.nlm.nih.gov
2. Giyose, P., 2013. Strategies used to implement the national guidelines on preventing and early management of multi-drug resistant tuberculosis (MDR-TB) at the buffalo city municipality clinics in East London Eastern Cape province. [PDF]
3. J. Sloan, D. & M. Lewis, J., 2016. Management of multidrug-resistant TB: novel treatments and their

- expansion to low resource settings. ncbi.nlm.nih.gov
4. Kolloli, A. & Subbian, S., 2017. Host-Directed Therapeutic Strategies for Tuberculosis. ncbi.nlm.nih.gov
 5. Yadav, P., 2023. Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review. ncbi.nlm.nih.gov
 6. Vishwakarma, D., Gaidhane, A., Sahu, S., & S Rathod, A., 2023. Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review. ncbi.nlm.nih.gov
 7. Karnan, A., Jadhav, U., Ghewade, B., Ledwani, A., & Shivashankar, P., 2024. A Comprehensive Review on Long vs. Short Regimens in Multidrug-Resistant Tuberculosis (MDR-TB) Under Programmatic Management of Drug-Resistant Tuberculosis (PMDT). ncbi.nlm.nih.gov